• TAS‐205 Safe, May Slow Muscle Loss in DMD Patients, Phase 2 Data Suggest
  • Addressing the Funding Crisis for Social Security
  • CureDuchenne Teams Up with Vivli to Share DMD Clinical Trial Data
  • FDA Accepts New Drug Application for Potential DMD Treatment Viltolarsen
  • FDA Efforts to Bring Patients into Treatment Decisions Focus of NORD Webinar
  • BIND Project Focuses on Brain Effects of Muscular Dystrophies
  • World Duchenne Organization Takes Lead in European Efforts to Better Treat DMD
  • Orsini Specialty Pharmacy Now Provides Vyondys 53 to Treat Duchenne
  • With Post-Brexit Move to Amsterdam Complete, EMA Renews Rare Disease Focus
  • From Care Centers to Research Awards and Summer Camp, MDA Leads by Helping Others
  • Combo Treatments, Gene Therapies and What’s Ahead for Muscular Dystrophy: Talk with MDA
  • Blocking IGF2R Protein Could Be Therapeutic Strategy, Improve Muscle Strength in DMD, Mouse Study Suggests